Paxlovid 10 days + REMDESIVIR for immunologic deficiency syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Oct 2022: Trial registered, NCT05587894
  2. 27 Apr 2023: Trial started, NCT05587894

The trials

NCT05587894: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

State
Under way
Phase
Phase 2
People
256 planned
Started
27 Apr 2023
Primary completion
31 Dec 2026
Arms
Nirmatrelvir/r 10 days + remdesivir s.d
Results
None posted
  1. 20 Oct 2022: Trial registered
  2. 27 Apr 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.